<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65275">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659138</url>
  </required_header>
  <id_info>
    <org_study_id>ACT12688</org_study_id>
    <secondary_id>2012-002013-19</secondary_id>
    <secondary_id>U1111-1124-1076</secondary_id>
    <nct_id>NCT01659138</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis</brief_title>
  <acronym>FUSCIA</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the efficacy of SAR339658

      Secondary Objective:

      To assess the safety of SAR339658
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of study period is 18 weeks, broken down as follows:  - 4 weeks for
      screening - 8 weeks for treatment - 6 weeks for the post treatment safety follow-up A
      post-study long term safety follow-up will be performed in the form of a phone interview at
      3, 6, 12, 18 and 24 months from the last administration of the study medication.  After
      completion of the 8-week treatment phase of this study, patients may be eligible to enter a
      long term safety study (LTS12593) for active treatment with SAR339658.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of Participants with Clinical Response by Mayo Score</measure>
    <time_frame>At Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Clinical Remission by Mayo Score</measure>
    <time_frame>At Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Mucosal Healing</measure>
    <time_frame>At Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>At Weeks 4 and 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Quality of Life (QoL) SF-36</measure>
    <time_frame>At Weeks 4 and 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the partial Mayo Score</measure>
    <time_frame>At Weeks 4 and 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with adverse events</measure>
    <time_frame>Up to Week 17</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>SAR339658</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose regimen every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR339658</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>SAR339658</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: o Male or Female ≥18  and ≤70 years old o History of active ulcerative
        colitis of at least 3 months duration o Active UC should be confirmed by colonoscopy or
        flexible sigmoidoscopy during the screening period within 7 days prior to randomization.
        o Moderate to severe ulcerative colitis at time of screening, confirmed by Mayo score ≥6
        to 12 and endoscopy subscore of ≥2 despite treatment with immunosuppressants and/or
        anti-TNFs:     o Immunosuppressants: Patient must be on concurrent treatment with or have
        had an inadequate response to (did not respond to or lost response to) or be intolerant to
        immunosuppressants such as azathioprine, 6-mercaptopurine, or methotrexate.     AND/OR
        o TNF-alpha antagonists: Patient must have had an inadequate response or lost response or
        be intolerant to TNF-alpha antagonists  o Fecal calprotectin ≥200mg/kg o Patients on
        corticosteroids must be on a stable dose ≥2 weeks prior to screening o Patients on
        azathioprine, 6- mercaptopurine or methotrexate must be on treatment for at least 12 weeks
        prior to screening; and on a stable dose ≥4 weeks prior to screening o Patients on oral
        5-aminosalicylates, mesalamine or sulfasalazine must be on a stable dose for ≥4 weeks
        prior to screening o Patients naïve to anti-TNF alpha or non responder (primary or
        secondary) or intolerant to anti-TNF alpha  o Signed written informed consent  Exclusion
        criteria: o Patients with Crohn's Disease (CD) o Diagnosis of indeterminate colitis o
        Patients with stool sample positive for ova, parasites, or positive culture for aerobic
        pathogens including: Aeromonas, Plesiomonas, Shigella, Yersinia, Campylobacter and E. Coli
        spp. or positive for Clostridium difficile B toxin in stools.   o Patients with prior
        colectomy or anticipated colectomy during their participation in the study o Presence of
        ileal pouch or ostomy o Fulminant disease or toxic megacolon o Colonic dysplasia except
        for adenoma o Total Parenteral Nutrition (TPN) o Cyclosporine, mycophenolate mofetil,
        sirolimus (rapamycin), thalidomide or tacrolimus within 2 months prior to screening o
        Previous exposure to natalizumab (Tysabri®) or vedolizumab o Antidiarrheals within 2 weeks
        prior to screening  o Prednisone &gt;40 mg/day (or equivalent) o Budesonide &gt;9 mg/day o
        Received intravenous corticosteroids within 2 weeks prior to screening or during screening
        o Rectally administered topical 5-aminosalicylate or corticosteroids within 4 weeks prior
        to screening o Received therapeutic enema or suppository, other than required for
        colonoscopy or flexible sigmoidoscopy within 4 weeks prior to screening or during
        screening o Antibiotics for UC or gastrointestinal infection within 4 weeks prior to
        screening  o Patient who has previously participated in any clinical trial of GBR500 /
        SAR339658 o Patient who has taken other investigational medications within 2 months or 5
        half lives, (whichever is longer) prior to screening o Use of any biologics for the
        treatment of UC in the previous 8 weeks before screening o Requirement for concomitant
        treatment that could bias primary evaluation o Pregnant or breast-feeding women o Women of
        childbearing potential not protected by highly effective contraceptive method of birth
        control   o Patient with latent or active tuberculosis (TB)  o Any signs or symptoms
        suggestive of active TB upon medical history or clinical examination o Patients with a
        positive QuantiFERON TB Gold Test o Chest radiograph within 3 months prior to the
        inclusion visit consistent with prior tuberculosis infection including, but not limited
        to, apical scarring, apical fibrosis, or multiple calcified granulomasa.  This does not
        include non-caseating granulomasa o Patients with close contact with a person with active
        tuberculosis o Patient with a history of listeriosis or tuberculosis (unless it is
        documented that they were adequately treated)  o Administration of any live (attenuated)
        vaccine within 3 months prior to the screening Visit (eg, varicella-zoster vaccine, oral
        polio, rabies) o Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core
        antibody (HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit o
        Prior opportunistic infections within six months prior to screening or while receiving
        anti-TNF treatment o History of a hypersensitivity reaction, other than localized
        injection site reaction (ISR), to any biological molecule o History or any current signs
        of demyelinating disease or any neurological disease that can by the opinion of
        Investigator interfere with study safety assessments including assessment for PML o
        Patients with bleeding disorders or known platelet dysfunction   The above information is
        not intended to contain all considerations relevant to a patient's potential participation
        in a clinical trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840057</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840065</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840031</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840059</name>
      <address>
        <city>Mission Hills</city>
        <state>California</state>
        <zip>91345</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840074</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840061</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840041</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>Miramar,</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840044</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840048</name>
      <address>
        <city>Winter Park,</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840053</name>
      <address>
        <city>Savannah,</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840078</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840070</name>
      <address>
        <city>Rochester Hills</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840060</name>
      <address>
        <city>Ocean Springs</city>
        <state>Mississippi</state>
        <zip>39564</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840024</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840080</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840051</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840071</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840018</name>
      <address>
        <city>Jacksonville,</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840089</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157-1071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840046</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840045</name>
      <address>
        <city>Phoenixville</city>
        <state>Pennsylvania</state>
        <zip>19460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840090</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840052</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840082</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840019</name>
      <address>
        <city>Pasadena,</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840088</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840038</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840068</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840079</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840034</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-2499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840064</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040003</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 040001</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Herentals</city>
        <zip>2200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124003</name>
      <address>
        <city>London</city>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124005</name>
      <address>
        <city>Ottawa</city>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124006</name>
      <address>
        <city>Saskatoon</city>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 124002</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250002</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250003</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250005</name>
      <address>
        <city>La Roche Sur Yon Cedex 9</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250004</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 250006</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276009</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276001</name>
      <address>
        <city>Berlin</city>
        <zip>14163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276004</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276005</name>
      <address>
        <city>Hamburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276007</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276010</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 276002</name>
      <address>
        <city>Neustadt</city>
        <zip>67433</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380003</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380001</name>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380002</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 380006</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616003</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616001</name>
      <address>
        <city>Gdynia</city>
        <zip>81-969</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616004</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616002</name>
      <address>
        <city>Lodz</city>
        <zip>90302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616005</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616007</name>
      <address>
        <city>Poznan</city>
        <zip>60539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616006</name>
      <address>
        <city>Sroda Wielkopolska</city>
        <zip>63-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 616008</name>
      <address>
        <city>Warszawa</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>August 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
